Экстрамедуллярные рецидивы после трансплантации аллогенных гемопоэтических клеток и трансфузий лимфоцитов донора

Larisa A. Kuzmina, Л С Любимова, Larisa Pavlovna Mendeleeva et al. · Клиническая онкогематология. Фундаментальные исследования и клиническая практика · 2011

SUMMARY The aim of the study was to investigate the frequency and the time of extramedullary relapses development after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and donor lymphocyte infusion (DLI) and to find the optimal treatment. 48 patients (35 — acute leukemia, 8 — chronic leukemia, 5 — myelodysplastic syndrome) after allo-HSCT performed during 2007–2010 were included. The median age was 32 (19–63) years, male / female — 24/24. In 44 cases donors were HLA-identical siblings, in 3 cases — syngeneic, in 1 case donor was 2 HLA-antigen incompatible. Conditioning regimen was myeloablative in 36 cases, nonmyeloablative in 14 cases. Median follow-up was 27 (8–45) months. 35 of 48 patients (72,9 %) are alive for the moment. The mortality was 27,1 % (13 patients). The main mortality cause was relapse, diagnosed only in patients with acute myeloid leukemia (AML) (in 48 % of patients with AML). It is important to note, that most patients with relapses received allo-HSCT in resistant / relapsed leukemia or in II remission. Extramedullary relapses, including isolated CNS relapses, were diagnosed in 15 % patients. More than a half of these relapses developed during or after bone marrow relapse. Median time between allo-HSCT and diagnosis of extramedullary relapse was 8 months. No signs of the disease were registered after isolated CNS relapses. In patients with granulocytic sarcoma effects were achieved only after chemotherapy with or without radiotherapy.

Cited by 0 works.

Authors

References